Literature DB >> 1314134

Chromosome abnormalities in human non-small cell lung cancer.

J R Testa1, J M Siegfried.   

Abstract

Clonal cytogenetic abnormalities found in 30 non-small cell lung carcinomas (NSCLC), including 28 newly diagnosed primary tumor specimens, are summarized. Multiple chromosome alterations were identified in every case, and 19 of 30 tumors had near-triploid or near-tetraploid karyotypes. Polysomy 7 and partial gains of 7p, including 7p11-p13 (site of the EGFR gene), were particularly frequent, occurring alone or in combination in 26 tumors. Recurrent losses involving 1p, 3p, 6q, 9p, 11p, 15p, and 17p (where the TP53 gene is located) were each seen in 16-25 cases. Five tumors exhibited double minutes, which were associated with amplified MYC1 (1 case) and EGFR (1 case), as determined by Southern analysis. The cytogenetic data were compiled from either short term cultures of tumor tissue harvested within 1-9 days (18 cases) or later harvests performed on long term cultures or cell lines (6 cases); in the other 6 cases results were obtained from both short term and long term cultures. Two studies were performed to validate the use of long term culture for cytogenetic analysis of solid lung tumors. First, in order to determine whether cytogenetic results from cultures are representative of the original tumor, the modal chromosome number of 13 specimens placed into culture was compared to the DNA index of the original tumor tissue, as measured by flow cytometry. The DNA indices of the solid tumor biopsies agreed with the degree of aneuploidy observed by cytogenetic analysis in every case. Second, in 6 cases we performed direct comparisons of karyotypes obtained from cells cultured by both methods. Identical chromosome abnormalities were detected in short term cultures and later harvests of the same specimen. Overall, our findings indicate that tumorigenesis in NSCLC is characterized by the accumulation of multiple chromosome alterations. Furthermore, these data demonstrate that recurrent cytogenetic changes can be identified in NSCLC and that detailed karyotypes from long term cultures are relevant to the original tumor. Chromosome abnormalities detected by these techniques may have clinical and biological significance. However, the complex pattern of karyotypic changes seen in newly diagnosed NSCLC emphasizes the need for future investigations of premalignant bronchial lesions in order to identify primary genetic changes important for early detection and intervention in this aggressive neoplasm.

Entities:  

Mesh:

Year:  1992        PMID: 1314134

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  19 in total

Review 1.  Double minutes, cytogenetic equivalents of gene amplification, in human neoplasia - a review.

Authors:  Erich Gebhart
Journal:  Clin Transl Oncol       Date:  2005-12       Impact factor: 3.405

2.  EGFR mutation is a better predictor of response to tyrosine kinase inhibitors in non-small cell lung carcinoma than FISH, CISH, and immunohistochemistry.

Authors:  Lynette M Sholl; Yun Xiao; Victoria Joshi; Beow Y Yeap; Leigh-Anne Cioffredi; David M Jackman; Charles Lee; Pasi A Jänne; Neal I Lindeman
Journal:  Am J Clin Pathol       Date:  2010-06       Impact factor: 2.493

Review 3.  The pathophysiology and management of spine metastasis from lung cancer.

Authors:  J S Greenberger
Journal:  J Neurooncol       Date:  1995       Impact factor: 4.130

4.  Interphase cytogenetics in paraffin sections of lung tumors by non-isotopic in situ hybridization. Mapping genotype/phenotype heterogeneity.

Authors:  S Y Kim; J S Lee; J Y Ro; M L Gay; W K Hong; W N Hittelman
Journal:  Am J Pathol       Date:  1993-01       Impact factor: 4.307

5.  Epidermal growth factor receptor gene amplification in atypical adenomatous hyperplasia of the lung.

Authors:  Maria G McIntire; Sandro Santagata; Keith Ligon; Lucian R Chirieac
Journal:  Am J Transl Res       Date:  2010-05-16       Impact factor: 4.060

6.  Evaluation of 7q31 region improves the accuracy of EGFR FISH assay in non small cell lung cancer.

Authors:  Laura Casorzo; Mara Corigliano; Paolo Ferrero; Tiziana Venesio; Mauro Risio
Journal:  Diagn Pathol       Date:  2009-11-04       Impact factor: 2.644

7.  Cancer-drug associations: a complex system.

Authors:  Ertugrul Dalkic; Xuewei Wang; Neil Wright; Christina Chan
Journal:  PLoS One       Date:  2010-04-02       Impact factor: 3.240

8.  Novel fluorescence in situ hybridization approaches in solid tumors. Characterization of frozen specimens, touch preparations, and cytological preparations.

Authors:  S Xiao; A Renshaw; E S Cibas; T J Hudson; J A Fletcher
Journal:  Am J Pathol       Date:  1995-10       Impact factor: 4.307

9.  Molecular testing guideline for selection of lung cancer patients for EGFR and ALK tyrosine kinase inhibitors: guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology.

Authors:  Neal I Lindeman; Philip T Cagle; Mary Beth Beasley; Dhananjay Arun Chitale; Sanja Dacic; Giuseppe Giaccone; Robert Brian Jenkins; David J Kwiatkowski; Juan-Sebastian Saldivar; Jeremy Squire; Erik Thunnissen; Marc Ladanyi
Journal:  J Thorac Oncol       Date:  2013-07       Impact factor: 15.609

10.  Molecular testing guideline for selection of lung cancer patients for EGFR and ALK tyrosine kinase inhibitors: guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology.

Authors:  Neal I Lindeman; Philip T Cagle; Mary Beth Beasley; Dhananjay Arun Chitale; Sanja Dacic; Giuseppe Giaccone; Robert Brian Jenkins; David J Kwiatkowski; Juan-Sebastian Saldivar; Jeremy Squire; Erik Thunnissen; Marc Ladanyi
Journal:  Arch Pathol Lab Med       Date:  2013-04-03       Impact factor: 5.534

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.